‘Magic mushroom’ compounds could help treat anorexia
Compounds derived from ‘magic mushrooms’ could be a potential treatment for anorexia nervosa, a study says.
A small pilot trial from the Centre for Psychedelic Research at Imperial College London indicates that psilocybin – the active ingredient in psychedelic ‘magic mushrooms’ – may have potential as a treatment for anorexia nervosa when combined with therapy.
The study, published in the British Journal of Psychiatry, looked at 21 women who had lived with anorexia nervosa for an average of 11 years and had not found long-term success with any previous treatments. On average, participants were 32 years old and had a BMI of 16.4 kg/m2.
All participants received three doses of oral psilocybin within a supportive therapeutic environment. The psilocybin sessions were supported with extensive talk therapy before and after dosing. This study did not include a control group.
Average eating disorder scores were reduced at every follow-up, and nearly all participants (18/21) showed improvements two weeks after the final session. At three months, 48% of participants had scores comparable to someone without an eating disorder. Participants also reported an increased motivation to recover that lasted for one year.
“This study delivered a brief programme of psilocybin dosing and therapeutic support over a six-week period,” Dr Hannah Douglass, a Postdoctoral Fellow at The University of Auckland who led the study.
‘Our results in individuals living with anorexia nervosa are encouraging, especially given that these participants had found previous treatments unsuccessful in maintaining their remission. However, further research is needed to assess how these findings might apply to a broader, more diverse population.”
Study offered participants chance to ‘approach treatment from a different angle’
During the six-week period, each participant received one ‘assumed inactive’ dose of psilocybin (1 mg, as a ‘placebo’) followed by two ‘high doses’ (25 mg) of psilocybin with two-week breaks in between. While participants knew they were receiving psilocybin, they did not know which dose was being administered at each session.
To track the long-term impact of the treatment, participants were assessed at two weeks, three months, six months, and one year after their final session. Changes in the severity of their eating disorder symptoms and motivation to recover were measured and their BMI was tracked for the first six weeks.
Psilocybin was found to be safe in this study, with headache and nausea the most common side effects. One participant, however, chose to drop out after their second dose.
Researchers emphasised that this was a small preliminary study without a drug-free comparison group, with results indicating the treatment was more beneficial for some than others.
“Having worked in the field of eating disorders for over 15 years it was encouraging to see that the trial, albeit with a very small cohort, provided an opportunity for individuals living with anorexia nervosa to approach treatment from a different angle,” said Jennifer Danby, who worked as the Lead Therapist on the trial.
“Anorexia often serves as a protective mechanism for people and we saw participants be able to explore their relationship with the illness and gain some new perspectives. By laying fertile ground for change, even minor adjustments can lead to promising change longer term.”
